Rhabdomyolysis due to interaction of simvastatin with mibefradil

Lancet. 1998 Jun 27;351(9120):1929-30. doi: 10.1016/S0140-6736(05)78613-X.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticholesteremic Agents / adverse effects*
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use
  • Calcium Channel Blockers / adverse effects*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channel Blockers / therapeutic use
  • Drug Interactions
  • Female
  • Humans
  • In Vitro Techniques
  • Mibefradil
  • Microsomes, Liver / drug effects
  • Rhabdomyolysis / chemically induced*
  • Simvastatin / adverse effects*
  • Simvastatin / pharmacology
  • Simvastatin / therapeutic use
  • Tetrahydronaphthalenes / adverse effects*
  • Tetrahydronaphthalenes / pharmacology
  • Tetrahydronaphthalenes / therapeutic use

Substances

  • Anticholesteremic Agents
  • Benzimidazoles
  • Calcium Channel Blockers
  • Tetrahydronaphthalenes
  • Mibefradil
  • Simvastatin